Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 11, 2018 16:45 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals to Host Investor & Analyst Day on September 20, 2018

DURHAM, N.C., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates...
September 04, 2018 16:05 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals Submits Supplemental New Drug Application for DOPTELET® (avatrombopag) for the Treatment of Chronic ITP

DURHAM, N.C., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates...
August 09, 2018 16:01 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals Reports Second Quarter 2018 Operating and Financial Results

DOPTELET approved by FDA on May 21, 2018 DOPTELET launched on June 4, 2018 Conference call scheduled for 4:30 p.m. ET today Investor & Analyst Day scheduled for September 20, 2018 in NYC ...
July 26, 2018 16:05 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 9, 2018

DURHAM, N.C., July 26, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) will host a conference call on Thursday, August 9, 2018 at 4:30 p.m. ET to discuss second quarter 2018...
June 25, 2018 07:00 ET | Source: Dova Pharmaceuticals, Inc.

Nancy J. Wysenski Joins Dova Pharmaceuticals’ Board of Directors

DURHAM, N.C., June 25, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Nancy J. Wysenski will join Dova’s Board of Directors effective immediately. In addition...
June 04, 2018 07:00 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals Announces Publication of Pivotal Phase 3 Data and Upcoming Congress Presentations for DOPTELET® (avatrombopag)

DURHAM, N.C., June 04, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the recent online publication of its pivotal Phase 3 trial data on the use of DOPTELET® ...
May 31, 2018 07:00 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals Announces Availability of DOPTELET® in the United States

DURHAM, N.C., May 31, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the availability of DOPTELET in the United States for the treatment of thrombocytopenia in...
May 29, 2018 17:00 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference

DURHAM, N.C., May 29, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the...
May 21, 2018 12:43 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals Announces U.S. FDA Approval of DOPTELET® (avatrombopag)

DURHAM, N.C., May 21, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the U.S. Food and Drug Administration (FDA) has completed their Priority Review and approved...
May 09, 2018 16:05 ET | Source: Dova Pharmaceuticals, Inc.

Dova Pharmaceuticals Reports First Quarter 2018 Operating and Financial Results

PDUFA date for avatrombopag of May 21, 2018 Conference call scheduled for 4:30 p.m. ET today DURHAM, N.C., May 09, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a...